DOCSLIB.ORG

Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations Supplementary Online Content Encinosa W, Davidoff AJ. Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. JAMA Oncol. Published online August 11, 2016. doi:10.1001/jamaoncol.2016.2530. eTable 1. Antineoplastics and Their Antiemetic Guidelines eTable 2. Descriptive Statistics Sample: Means and Proportions eTable 3. Logit-Estimated Effect of Choosing Wisely on Antiemetic Overuse eAppendix. Log of Statistical Analyses (Stata 14.0) This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 1. Antineoplastics and Their Antiemetic Guidelinesa Chemotherapy Induced Nausea ASCO and NCCN Antiemetic 2012 and 2015 Operational & Vomiting Risk Category & Therapy Definitions of Choosing Wisely Individual Antineoplastic Agents Antiemetic Overuse IV Chemotherapy High risk A. 5HT3-RA (dolasetron, Carboplatinb granisetron, ondansetron, or Cisplatinc palonosetron), steroid Cyclophosphamidec,d (dexamethasone) and NK1-RA Use of metaclopramide, Dacarbazine (aprepitant, fosaprepitantor, or prochloperazine, or haloperidol in Doxorubicinc rotapitant); addition to recommended Irinotecanb B. Netupitant with palonosetron and antiemetics Methotrexateb,c dexamethasone; or C. 2015 NCCN: olanzapine with palonosetron and dexamethasone Moderate risk Azacitidine Same as above, with NK1-RA Same as above Bendamustine hydrochloride optional in A Oxaliplatin Low risk ASCO: dexamethasone Bortezomibe Docetaxel NCCN: dexamethasone, Fluorouracil metoclopramide or prochlorperazine 2012: use of NK1-RA or 5HT3-RA Gemcitabine Mitomycin 2015 NCCN: dexamethasone, 2015: use of NK1-RA, netupitant, Paclitaxel metoclopramide, prochlorperazine, olanzapine, or palonosetron Pemetrexed or 5HT3-RA (dolasetron, granisetron, or ondansetron) Minimal risk Bevacizumab Use of NK1-RA, steroids, netupitant, olanzapine, or 5HT3- Rituximab No routine prophylaxis Bleomycin RA; use of metaclopramide, prochloperazine, or haloperidol Trastuzumab Oral Chemotherapy High to moderate risk Use of NK1-RA, steroids, Cyclophosphamidec netupitant, olanzapine, or NCCN: 5HT3-RA c palonosetron; use of Temozolomide (dolasetron, granisetron, or metaclopramide, prochloperazine, ondansetron) or haloperidol in addition to recommended antiemetics Low to minimal risk Capecitabine Chlorambucil Erlotinib Hydroxyurea NCCN: haloperidol, 2012: use of NK1-RA, steroids, or Imatinib mesylate metoclopramide, or prochlorperazine 5HT3-RA Lenalidomide Melphalan 2015 NCCN: haloperidol, 2015: use of NK1-RA, steroids, Mercaptopurine metoclopramide, prochlorperazine, netupitant, olanzapine, or or 5HT3-RA (dolasetron, Methotrexate palonosetron Sorafenib tosylate granisetron, or ondansetron) Sunitinib malate Thalidomide Dasatinib Pazopanib Abbreviations: 5HT3-RA, serotonin receptor antagonist; ASCO, American Society of Clinical Oncology; CINV, chemotherapy-induced nausea and vomiting; IV, intravenous; NCCN, National Comprehensive Cancer Network; NK1- RA, neurokinin-1 receptor antagonist. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 aBased on ASCO and National Comprehensive Cancer Network guidelines.17-22 bThis agent is a lower risk under ASCO but under National Comprehensive Cancer Network can be high risk for certain patients, so we assign it as high risk. cThis agent’s National Comprehensive Cancer Network risk varies by dose per surface area, but we assign it to its highest risk class. dASCO: the anthracyclines combined with cyclophosphamide are included here. eBortezomib is minimal risk under ASCO. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 2. Descriptive Statistics Sample: Means and Proportions Characteristic Proportion or Mean (SD) No. of patients receiving chemotherapy 678,220 Overuse 0.241 (0.429) Intravenous chemotherapy, high to moderate CINV risk 0.486 (0.500) Intravenous chemotherapy, low CINV risk 0.148 (0.355) Intravenous chemotherapy, minimal CINV risk 0.144 (0.351) Oral chemotherapy, high to moderate CINV risk 0.023 (0.150) Oral chemotherapy, low to minimal CINV risk 0.200 (0.400) Medicare enrolled 0.321 (0.467) Chemotherapy given in hospital 0.241 (0.427) Out-of-network chemotherapy 0.133 (0.340) Fee for service 0.129 (0.336) Preferred provider organization 0.633 (0.482) Point of service 0.054 (0.226) Health maintenance organization 0.132 (0.338) High deductible plan 0.051 (0.221) Union 0.129 (0.336) Hourly 0.164 (0.370) Rural 0.154 (0.361) Northeast 0.200 (0.400) North Central 0.267 (0.442) South 0.357 (0.479) West 0.176 (0.381) Age 59.5 (13.6) Female 0.582 (0.493) No. of chronic conditions = 0 0.168 (0.374) No. of chronic conditions = 1 0.668 (0.471) No. of chronic conditions = 2 0.094 (0.292) No. of chronic conditions = 3 0.046 (0.210) No. of chronic conditions ≥4 0.023 (0.151) Abbreviation: CINV, chemotherapy induced nausea and vomiting © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 3. Logit-Estimated Effect of Choosing Wisely on Antiemetic Overusea Characteristicb Odds Ratio (95% CI) No. of patients receiving chemotherapy 678,220 Pre-Choosing Wisely baseline period Not applicable 6-mo transition period after Choosing Wisely 0.930c (0.905, 0.956) Post-Choosing Wisely period (after 6 mo) 1.074c (1.046, 1.102) Oral chemotherapy, low to minimal CINV risk 0.566c (0.472, 0.678) Intravenous chemotherapy, high to moderate CINV risk 1.672c (1.527, 1.830) Intravenous chemotherapy, low CINV risk 2.791c (2.281, 3.415) Intravenous chemotherapy, minimal CINV risk 10.83c (3.834, 30.58) Medicare enrolled 0.898c (0.874, 0.924) Chemotherapy administered in hospital outpatient department 0.765c (0.754, 0.776) Out-of-network chemotherapy 0.889c (0.872, 0.907) Preferred provider organization 0.997 (0.974, 1.020) Point of service 0.907c (0.877, 0.938) Health maintenance organization 1.201c (1.168, 1.234) High deductible plan 1.147c (1.108, 1.188) Union 1.252c (1.221, 1.283) Hourly 1.502c (1.469, 1.535) Rural 1.069c (1.051, 1.087) North Central 1.299c (1.276, 1.323) South 0.911c (0.895, 0.927) West 1.085c (1.063, 1.107) Age 49-56 y 0.964c (0.946, 0.982) Age 57-61 y 0.942c (0.923, 0.961) Age 62-69 y 0.932c (0.908, 0.957) Age ≥70 y 0.863c (0.834, 0.894) Female 1.033c (1.017, 1.049) No. of chronic conditions = 1 0.808c (0.796, 0.821) No. of chronic conditions = 2 0.828c (0.809, 0.847) No. of chronic conditions = 3 0.784c (0.760, 0.809) No. of chronic conditions ≥4 0.761c (0.729, 0.794) Month 1.000 (1.000, 1.001) aChoosing Wisely baseline, oral chemotherapy with high to moderate CINV risk, fee for service, Northeast, age 18-48 y, and number of chronic conditions = 0 were omitted. bFixed effects for 135 antineoplastic agents and 36 cancer sites are not shown. cStatistically different from 0 at P < .01. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eAppendix. Log of Statistical Analyses (Stata 14.0) 1. Specification tests for Probit model. Probit xi: quietly probit overuse choosewise1 choosewise2 i.risk medicare hospital outofnetwork i.plan union hourly rural i.region i.acat i.sex i.ncc month /*cancer site fixed effects*/ cancer11_head_sum_sum cancer12_esopha_sum_sum cancer13_stomach_sum_sum cancer14_colon_sum_sum cancer15_rectum_sum_sum cancer16_liver_sum_sum cancer17_pancreas_sum_sum cancer18_gi_sum_sum cancer19_lung_sum_sum cancer20_respiratory_sum_sum cancer21_bone_sum_sum cancer22_skin_sum_sum cancer24_breast_sum_sum cancer25_uterus_sum_sum cancer26_cervix_sum_sum cancer27_ovary_sum_sum cancer28_otherf_sum_sum cancer29_prostate_sum_sum cancer30_testis_sum_sum cancer32_bladder_sum_sum cancer33_kidney_sum_sum cancer34_otheruri_sum_sum cancer35_brain_sum_sum cancer36_thyroid_sum_sum cancer37_hodgkin_sum_sum cancer38_lymphoma_sum_sum cancer390_leukemias_sum_sum cancer391_cml_sum_sum cancer40_myeloma_sum_sum cancer41_other_sum_sum cancer42_secondarym_sum_sum cancer43_mneoplasmwo_sum_sum cancer440_neoplasmsun_sum_sum cancer441_mds_sum_sum /*chemo drug fixed effects*/ i.c1 ; linktest, nolog; Probit regression Number of obs = 677,676 LR chi2(2) = 127628.49 Prob > chi2 = 0.0000 Log likelihood = -311249.53 Pseudo R2 = 0.1701 ------------------------------------------------------------------------------ overuse | Coef. Std. Err. z P>|z| [95% Conf. Interval] -------------+---------------------------------------------------------------- _hat | 1.015991 .0079212 128.26 0.000 1.000466 1.031516 _hatsq | .0088328 .0038959 2.27 0.023 .001197 .0164685 _cons | .0037831 .0031593 1.20 0.231 -.002409 .0099753 ------------------------------------------------------------------------------ Here, _hat is the linear predicted outcome from the above first probit regression. In this Tukey-Pregibon link test, _hat is significant, indicating that the linear combination of covariates in the above probit does a good job at predicting overuse. However, _hatsq (the square of _hat) is also significant, indicating that nonlinear combinations of the covariates also predict probits of overuse. The probit model requires the probits to be a linear combination of the covariates. Thus, the probit model is mis-specified. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 2. Specification tests for Logit model. Logit xi: quietly
Load more

Recommended publications
  • CP.PMN.158 Netupitant and Palonosetron (Akynzeo)
    Clinical Policy: Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) Reference Number: CP.PMN.158 Effective Date: 09.01.06 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Netupitant/palonosetron (Akynzeo®) and fosnetupitant/palonosetron are fixed combination products of netupitant, a substance P/neurokinin 1 (NK1) receptor antagonist, and palonosetron hydrochloride, a serotonin (5-HT3) receptor antagonist. FDA Approved Indication(s) Akynzeo capsules are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Akynzeo for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Akynzeo is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Prevention of Nausea and Vomiting Associated with Cancer Chemotherapy (must meet all): 1. Prescribed for the prevention of chemotherapy-induced nausea/vomiting; 2. Age ≥ 18 years; 3. If request is for Akynzeo capsules, member is scheduled to receive moderately to highly emetogenic cancer chemotherapy (see Appendix D); 4. If request is for Akynzeo for injection, member is scheduled to receive highly emetogenic cancer chemotherapy (see Appendix D); 5.
    [Show full text]
  • Akynzeo™ (Netupitant and Palonosetron) Capsule/ Antiemetics
    Drug Monograph Drug/Drug Akynzeo™ (netupitant and palonosetron) capsule/ Class: Antiemetics Prepared for: MO HealthNet Prepared by: Xerox Heritage, LLC New Criteria Revision of Existing Criteria Executive Summary The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open Purpose: access basis to prescribers, require a clinical edit or require prior authorization for use. Akynzeo™ is available as a 300 mg/0.5 mg capsule containing 300 mg of netupitant and 0.5 mg of palonosetron respectively. Dosage Forms & Manufacturer: Eisai Inc, Woodcliff Lake, NJ The efficacy of Akynzeo™ for the prevention of acute and delayed nausea and vomiting due to chemotherapy was demonstrated in two phase 3 clinical trials. Complete response rates (ie, no emesis and no rescue medication) for acute, delayed, and overall nausea and vomiting following a single cycle of moderately emetogenic chemotherapy (n=1455) were 88.4%, 76.9%, and 74.3% for Akynzeo™ plus dexamethasone compared Summary of with 85%, 69.5%, and 66.6% for palonosetron plus dexamethasone. In a Findings: second phase 3 study where patients were randomized to receive Akynzeo™ or aprepitant plus palonosetron (with all patients receiving dexamethasone) for repeated cycles of highly or moderately emetogenic chemotherapy (n=412), complete response rates for the overall phase of nausea and vomiting ranged from 81% to 92% for the Akynzeo™ arm and 76% to 88% for the aprepitant/palonosetron arm through 6 cycles of chemotherapy. Status Prior Authorization (PA) Required Open Access Recommendation: Clinical Edit PDL Type of PA Increased Risk of ADE Preferred Agent Criteria: Appropriate Indications Under Solicitation 2015 Xerox Heritage, LLC All Rights Reserved.
    [Show full text]
  • Comparative Study of Palonosetron and Ondansetron in Prevention of Post Operative Nausea and Vomiting After Laparoscopic Gynaecological Surgeries
    Indian Journal of Clinical Anaesthesia 2020;7(1):59–63 Content available at: iponlinejournal.com Indian Journal of Clinical Anaesthesia Journal homepage: www.innovativepublication.com Original Research Article Comparative study of palonosetron and ondansetron in prevention of post operative nausea and vomiting after laparoscopic gynaecological surgeries Ankita Choudhary1,*, Vinod Parashar1 1Dept. of Anaesthesiology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India ARTICLEINFO ABSTRACT Article history: Introduction: Post operative nausea and vomiting (PONV) is a common complication after general Received 13-04-2019 anaesthesia, specially post laparoscopic surgeries. This study compared efficacy of palonosetron with Accepted 20-11-2019 ondansetron for prevention and management of PONV in patients undergoing laparoscopic gynaecological Available online 28-02-2020 surgeries. Materials and Methods : 100 patients, undergoing laparoscopic gynaecological surgery were randomly divided in 2 groups of 50 each. They received either ondansetron(4mg IV) or palonosetron (0.075mg IV) Keywords: before induction of general anaesthesia. They were monitored post operatively till 72 hours for episodes of Palonosetron nausea, vomiting, overall PONV and adverse effects. Post operative nausea vomiting Result: The incidence of overall PONV was significantly less in patients who received palonosetron as Laparoscopic gynaecological compared those who received ondansetron. Also, ondansetron group demonstrated higher use of rescue surgeries anti-emetic drug as compared with palonosetron group. No significant difference was found in incidence Anti-emetic drugs of adverse effects in both groups. Ondansetron Conclusion: Palonosetron, having longer duration of action, is more effective in treating long term PONV compared to ondansetron in patients undergoing laparoscopic gynaecological surgeries under general anesthesia. © 2020 Published by Innovative Publication.
    [Show full text]
  • Economic Analysis of Palonosetron Versus
    Shimizu et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:31 https://doi.org/10.1186/s40780-018-0128-9 RESEARCHARTICLE Open Access Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial) Hisanori Shimizu1,13* , Kenichi Suzuki2, Takeshi Uchikura1, Daiki Tsuji3, Takeharu Yamanaka4, Hironobu Hashimoto5, Koichi Goto6, Reiko Matsui7, Nobuhiko Seki8, Toshikazu Shimada9, Shunya Ikeda10, Naoki Ikegami11, Toshihiro Hama2, Nobuyuki Yamamoto12 and Tadanori Sasaki1 Abstract Background: We conducted an economic assessment using test data from the phase III TRIPLE study, which examined the efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part of a standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy (HEC). Methods: We retrospectively investigated all medicines prescribed for antiemetic purposes within 120 h after the initiation of cisplatin administration during hospitalization. In the TRIPLE study, patients were assigned to treatment with granisetron (GRA) 1 mg (n = 413) or palonosetron (PALO) 0.75 mg (n = 414). The evaluation measure was the cost-effectiveness ratio (CER) assessed as the cost per complete response (CR; no vomiting/ retching and no rescue medication). The analysis was conducted from the public healthcare payer’s perspective. Results: The CR rates were 59.1% in the GRA group and 65.7% in the PALO group (P = 0.0539), and the total frequencies of rescue medication use for these groups were 717 (153/413 patients) and 573 (123/414 patients), respectively.
    [Show full text]
  • ALOXI, INN-Palonosetron
    SCIENTIFIC DISCUSSION 1. Introduction Aloxi contains palonosetron, a 5-hydroxytryptamine (serotonin) type 3 receptor antagonist, as active substance. With the present application, the applicant sought a marketing authorisation in the following indication: - “the prevention of acute nausea and vomiting associated with initial and repeat course of moderately and highly emetogenic cancer chemotherapy and - the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy.” Chemotherapy-induced nausea and vomiting (CINV) CINV can be broadly categorised as acute, when nausea and vomiting occur within 24 hours after the start of chemotherapy [1], delayed, if CINV persist for 6 to 7 days after therapy [2, 3], or anticipatory, if CINV occur prior to chemotherapy administration [2, 4]. Chemotherapy agents have a highly variable emetogenic potential and can be classified according to their emetogenic level as agents with low, intermediate and high emetogenic risk. CINV remains a significant side effect experienced by cancer patients especially when treated with highly emetogenic regimens. It can impair patient’s quality of life and in case it becomes serious, dehydration, malnutrition, metabolic disturbances, and aspiration pneumonia may occur. As a consequence, control of nausea and vomiting plays an important part in the overall treatment success for cancer patients. The precise mechanisms by which chemotherapy induces nausea and vomiting are unknown. However, it appears probable that different chemotherapeutic agents act at different sites and that some chemotherapeutic agents act at multiple sites [5]. The mechanisms by which chemotherapeutic agents cause nausea and vomiting are activation of the chemoreceptor trigger zone (CTZ) either directly or indirectly, peripheral stimulation of the gastrointestinal tract, vestibular mechanisms, cortical mechanisms, or alterations of taste and smell [6].
    [Show full text]
  • Aloxi ® Palonosetron Hcl Injection
    Aloxi ® Palonosetron HCl injection DESCRIPTION Aloxi (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a selective serotonin subtype 3 (5-HT3) receptor antagonist with a strong binding affinity for this receptor. Chemically, palonosetron hydrochloride is: (3aS)-2-[(S)-1-Azabicyclo [2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1- oxo-1Hbenz[de]isoquinoline hydrochloride. The empirical formula is C19H24N2O.HCl, with a molecular weight of 332.87. Palonosetron hydrochloride exists as a single isomer and has the following structural formula: Palonosetron hydrochloride is a white to off-white crystalline powder. It is freely soluble in water, soluble in propylene glycol, and slightly soluble in ethanol and 2-propanol. Aloxi injection is a sterile, clear, colorless, non-pyrogenic, isotonic, buffered solution for intravenous administration. Each 5-ml vial of Aloxi injection contains 0.25 mg palonosetron base as hydrochloride, 207.5 mg mannitol, disodium edetate and citrate buffer in water for intravenous administration. The pH of the solution is 4.5 to 5.5. CLINICAL PHARMACOLOGY Pharmacodynamics Palonosetron is a selective 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.
    [Show full text]
  • AKYNZEO® Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------DOSAGE FORMS AND STRENGTHS-------------­ These highlights do not include all the information needed to use Capsules: 300 mg netupitant/0.5 mg palonosetron AKYNZEO® safely and effectively. See full prescribing information for For Injection: 235 mg fosnetupitant/0.25 mg palonosetron lyophilized AKYNZEO®. powder in a single-dose vial for reconstitution (3) AKYNZEO® (netupitant and palonosetron) capsules, for oral use ---------------------CONTRAINDICATIONS-----------------------­ Initial U.S. Approval: 2014 None (4) AKYNZEO® (fosnetupitant and palonosetron) for injection, for -----------------WARNINGS AND PRECAUTIONS-----------------­ intravenous use Hypersensitivity reactions, including anaphylaxis, have been reported in Initial U.S. Approval: 2018 patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor ---------------------RECENT MAJOR CHANGES-----------------------­ antagonists. (5.1) Indication and Usage (1) 04/2018 Serotonin syndrome has been reported with 5-HT3 receptor antagonists Dosage and Administration, Recommended Dosage (2.1) 04/2018 alone but particularly with concomitant use of serotonergic drugs. If such Dosage and Administration, Preparation (2.2) 04/2018 symptoms occur, discontinue AKYNZEO and initiate supportive Dosage and Administration, Incompatibility (2.3) 04/2018 treatment. If concomitant use of AKYNZEO with other serotonergic drugs is clinically warranted, patients should be made aware of a potential ---------------------INDICATIONS AND USAGE-----------------------­ increased risk for serotonin syndrome. (5.2, 7.3) AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting -------------------------ADVERSE REACTIONS---------------------------­ associated with initial and repeat courses of cancer chemotherapy, Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, including, but not limited to, highly emetogenic chemotherapy.
    [Show full text]
  • Palonosetron-Induced Anaphylaxis During General Anesthesia
    Case Report Allergy Asthma Immunol Res. 2017 January;9(1):92-95. https://doi.org/10.4168/aair.2017.9.1.92 pISSN 2092-7355 • eISSN 2092-7363 Palonosetron-Induced Anaphylaxis During General Anesthesia: A Case Report Hyungjun Park,2 Kyunghwan Oh,2 Hoonhee Lee,2 Ji-Hyang Lee,2 Sun-myoung Kang,2 So-Young Park,1 Hyouk-Soo Kwon,1 You Sook Cho,1 Hee-Bom Moon,1 Tae-Bum Kim1* 1Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Palonosetron is a 5-hydroxytryptamine-3 (5-HT-3) receptor antagonist used for preventing postoperative nausea and vomiting. Compared with on- dansetron and granisetron, it is a better drug because of prolonged action and minimal side effects. Some adverse effects of palonosetron have been reported. In this report, we describe a 37-year-old male who developed severe hypersensitivity reactions to palonosetron during surgery for kidney donation. His medical history was unremarkable, except for inguinal hernia with herniorrhaphy 8 years ago. The surgery was uneventful until 2 hours 20 minutes. After palonosetron injection, his blood pressure dropped to 80/50 mmHg, and facial edema, rash, conjunctival swelling, and wheezing developed.
    [Show full text]
  • Nitrous Oxide–Related Postoperative Nausea and Vomiting Depends on Duration of Exposure
    Nitrous Oxide–related Postoperative Nausea and Vomiting Depends on Duration of Exposure Philip J. Peyton, M.D., Ph.D., M.B.B.S., F.A.N.Z.C.A., Christine Yx Wu, M.B.B.S. ABSTRACT Background: Inclusion of nitrous oxide in the gas mixture has been implicated in postoperative nausea and vomiting (PONV) in numerous studies. However, these studies have not examined whether duration of exposure was a significant covariate. This distinction might affect the future place of nitrous oxide in clinical practice. 5 Methods: PubMed listed journals reporting trials in which patients randomized to a nitrous oxide or nitrous oxide–free anes- thetic for surgery were included, where the incidence of PONV within the first 24 postoperative hours and mean duration of Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/120/5/1137/265666/20140500_0-00022.pdf by guest on 26 September 2021 anesthesia was reported. Meta-regression of the log risk ratio for PONV with nitrous oxide (lnRR PONVN2O) versus duration was performed. Results: Twenty-nine studies in 27 articles met the inclusion criteria, randomizing 10,317 patients. There was a significant 120 2 relationship between lnRR PONVN2O and duration (r = 0.51, P = 0.002). Risk ratio PONV increased 20% per hour of nitrous oxide after 45 min. The number needed to treat to prevent PONV by avoiding nitrous oxide was 128, 23, and 9 where duration was less than 1, 1 to 2, and over 2 h, respectively. The risk ratio for the overall effect of nitrous oxide on PONV was 1.21 (CIs, 1.04–1.40); P = 0.014.
    [Show full text]
  • Nitrous Oxide and Post-Operative Nausea and Vomiting: a Randomized Controlled Trial
    Nitrous Oxide and Post-Operative Nausea and Vomiting: A Randomized Controlled Trial Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Natalie Marie Alsup, DMD Graduate Program in Dentistry The Ohio State University 2016 Thesis Committee: Simon Prior, BDS, MS, PhD, Advisor William M. Johnston, MS, PhD Megann Smiley, DMD, MS Copyright by Natalie Marie Alsup 2016 Abstract Purpose: To investigate the degree of postoperative nausea and vomiting (PONV) experienced in two different groups of patients having general anesthesia, one with 50 % nitrous oxide in the administered gas mixture and one without nitrous oxide. Methods: Twenty adult volunteers, American Society of Anesthesiology (ASA) physical classification I-II and aged 18-32 years, who had previously consented to oral & maxillofacial surgery with general anesthesia at The Ohio State University Oral & maxillofacial Surgery Department, were invited to participate in this clinical research study. Two general anesthesia groups were used: Nitrous Oxide Group – 50% nitrous oxide, sevoflurane, and oxygen; and Control Group – oxygen and sevoflurane. Subjects were divided into the 2 groups via systematic random assignments. Patients were induced for general anesthesia with propofol 2mg/kg IV, fentanyl 0.5mcg/kg IV, and succinylcholine 1 mg/kg IV. Following induction, all subjects were intubated and administered dexamethasone 4 mg IV. Following emergence from general anesthesia, the patients were transferred to the Post Anesthesia Care Unit (PACU). No additional antiemetics were administered prior to arrival and assessment in the PACU. Patients’ incidence of vomiting and self-reported nausea scores were recorded using a Verbal Numeric Rating Scale (VNRS) with a range of 0-10 every 15 minutes from the arrival to PACU until discharge, for a minimum of 60 minutes.
    [Show full text]
  • Chemotherapy Induced Nausea and Vomiting (CINV)
    Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2 Jan 2016 Document No: NESCNCHEM 001 Current Version: 2.4 Chemotherapy Group / Authors Steve Williamson/ Calum Polwart Approved by: Denise Blake Date Approved: 12/03/18 Review Date: 12/03/21 Summary of Changes Added missing cross references. Added radiotherapy increased emetogenicity & reduced emetogenicity of 1.2a carboplatin. 1.3 Updated guidance to reflect agreed changes to policy regarding dose of dexamethasone and NECDAG approval of aprepitant and palonosetron to match MASCC, ASCO and NCCN guidelines. Added antiemetic ladder as an appendix. 1.4 Updated format, added fosaprepitant and reference to MASSC 2010 guidelines updated table of emetogenicity 1.5 Added reference to oral formulation of palonsetron Updated to reference infusion of ondansetron and revised dose schedule. Plus metoclopramide EMA 2.0 recommendations. Added reference to Akynzeo® (netupitant and palonosetron) as alternative to palonsetron + aprepitant, reformatted 2.1 and general updates 2.2 Changed summary table to localised Version of ASCO table, removed level 5 risk, 2.3 Typos corrected 2.4 Olanzapine added as a breakthrough option 2.5 carboplatin ≥ AUC4 added to high risk (3 drug combination) as option. For more information regarding this document, please contact: Northern Cancer Alliance NHS England, Waterfront 4, Goldcrest Way, Newcastle Upon Tyne, NE15 7NY Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Summary – Standard Antiemetic Cover Minimal Emetic Risk: 2-Chlorodeoxyadenosine, bevacizumab, bleomycin, busulfan, cetuximab, fludarabine, rituximab, vinblastine, vincristine, vinorelbine No antiemetic should be administered routinely before or after chemotherapy.
    [Show full text]
  • 5-HT3 ANTAGONISTS Aloxi Injection (Palonosetron), Anzemet* Tablets
    5-HT3 ANTAGONISTS Aloxi injection (palonosetron), Anzemet* tablets (dolasetron), Granisetron injection, Kytril tablets, Sancuso patch, Sustol injection (granisetron), Zofran, Zuplenz oral film* (ondansetron) * Prior authorization for the brand formulation applies only to formulary exceptions due to being a non-covered medication. RATIONALE FOR INCLUSION IN PA PROGRAM Background Selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonists are antinauseant and anti-emetic agents with little or no affinity for other serotonin receptors, making them very useful in the treatment of nausea and vomiting. Often, these agents are used in the treatment of nausea and vomiting associated with chemotherapy in the treatment of cancer, as many of these 5-HT3 receptors are located centrally in the chemoreceptor trigger zone. 5-HT3 receptors are also located peripherally on vagal nerve terminals as well as on enteric neurons in the GI tract. When activated, they stimulate GI secretions and vagal afferent discharge, which induces vomiting. 5-HT3 antagonists block this from occurring (1). Regulatory Status FDA approved indications: Aloxis, Anzemet, Granisetron, Kytril, Sancuso, Sustol, Zofran, and Zuplenz are serotonin-3 (5-HT3) receptor antagonists indicated for the prevention and treatment of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy or post-operative nausea and vomiting (2 -10). Off-label use of ondansetron for the treatment of nausea and vomiting of pregnancy during the first trimester did not increase the risk of specific birth defects (11). Summary Selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonists are antinauseant, and anti-emetic agents with little or no affinity for other serotonin receptor, making them very useful in the treatment of nausea and vomiting.
    [Show full text]